Fineotex Q1: acquisition drives consolidated PAT +93% to ₹48 Cr, but margins compress
PAT +92.6% YoY · revenue +174.8% · margins compressing
₹376.63 Cr
+174.8% YoY
₹48.21 Cr
+92.6% YoY
12.47%
-4.7pp YoY
₹0.41
Fineotex reported consolidated revenue of ₹376.63 Cr, up 174.8% YoY and 20% QoQ, with PAT of ₹48.21 Cr (+92.6% YoY, +10.1% QoQ) — but the surge is almost entirely inorganic. The newly-consolidated CrudeChem Technologies (CCT) oil & gas platform and twelve other subsidiaries contributed ₹310.83 Cr of revenue and ₹27.68 Cr of PAT (pre-elimination) this quarter. The core standalone (Indian textile-chemical) business actually shrank: standalone revenue was ₹85.15 Cr, down 13.3% YoY and 12.8% QoQ, with standalone PAT of ₹20.53 Cr up just 3.2%. Consolidated and standalone therefore tell materially different stories — the headline growth is scale bought through acquisition, not organic momentum in the legacy business.
Q1 FY-2027 vs prior quarters
The mix shift into lower-margin oil & gas reset profitability: consolidated NPM fell to 12.5% from 17.1% a year ago (13.6% last quarter), and operational EBITDA margin was ~15.7% vs 18.4% YoY (though up from 13.9% QoQ, a sequential recovery). Owner-attributable PAT was ₹38.40 Cr, up 54.8% YoY — well below the +92.6% headline — because non-controlling interests took ₹9.81 Cr (≈20%) as CCT and the Malaysia units are not wholly owned. Reported EPS of ₹0.41 (vs ₹1.09 year-ago) reflects a roughly 5x expansion in share count (paid-up capital ₹116.45 Cr vs ₹22.92 Cr), so the per-share figure is not comparable YoY.
The stock went into the print at ₹47.43, up 13.2% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.
Management provided a very optimistic outlook, projecting revenue to potentially reach INR 3,000 crores in 3-4 years, driven by organic growth and the strategic acquisition of CrudeChem Technologies (CCT). They anticipate CCT to contribute significantly, aiming for USD 200 million in revenue by FY28, with EBITDA margin
— This quarter: met
Management's May concall guided toward ₹3,000 Cr revenue in 3-4 years, with CCT reaching USD 200m by FY28 and blended EBITDA of 18-20%; this quarter's ~₹1,500 Cr annualised run-rate and 130.8% consolidated volume growth track that thesis, though the current blended margin (~15.7%) still sits below the 18-20% target. No published street consensus exists for this ~₹4,500 Cr small-cap; the stock fell ~5% post-result as the market read the margin reset over the topline. Alongside the results, the board approved the 23rd AGM (Sep 11), a ₹0.05/share final dividend (record date Sep 4) and a fund-raising proposal.
W1
Blended EBITDA margin trajectory toward management's 18-20% target — currently ~15.7% as oil & gas mix dilutes
W2
Standalone core recovery — reversing the -13.3% YoY revenue decline (₹85.15 Cr) in the legacy textile-chemical business
W3
Minority leakage — NCI absorbed ₹9.81 Cr (20%) of PAT; watch owner-share vs headline PAT gap as subsidiaries scale
Informational and educational content only. Not investment advice.